AIM:To investigate the clinical characteristics and treatment outcomes,including visual function and overall survival(OS)of patients with ocular adnexal diffuse large B-cell lymphoma(OA-DLBCL).METHODS:This retrospecti...AIM:To investigate the clinical characteristics and treatment outcomes,including visual function and overall survival(OS)of patients with ocular adnexal diffuse large B-cell lymphoma(OA-DLBCL).METHODS:This retrospective cohort study enrolled 29 patients diagnosed with OA-DLBCL based on histopathological biopsy between 2006 and 2023.Patients were stratified into two subgroups:primary OA-DLBCL(no prior history of lymphoma)and secondary OA-DLBCL(history of DLBCL at non-ocular adnexal sites).OS was defined as the time interval from OA-DLBCL diagnosis to death from any cause.Survival analysis was performed using the Kaplan–Meier method,and prognostic factors affecting OS were identified using multivariate Cox proportional hazards regression with a stepwise selection approach.RESULTS:The cohort included 24 patients with primary OA-DLBCL(13 males,11 females;mean age:61.36±18.29y)and 5 patients with secondary OA-DLBCL(2 males,3 females;mean age:50.94±18.17y).Among the primary OA-DLBCL subgroup,12 patients(50%)presented with advanced disease(Ann Arbor stage IIIE–IV),and 16 patients(66%)were classified as T4 disease according to the tumor-node-metastasis(TNM)staging system.The mean final visual acuity was 1.72±1.10 in the primary group and 0.90±1.18 in the secondary group.The 5-year OS rate for the entire cohort was 27.7%.Multivariate analysis identified five factors significantly associated with poor survival outcomes:epiphora[adjusted hazard ratio(aHR),36.95],atherosclerotic cardiovascular disease(aHR,10.08),human immunodeficiency virus(HIV)infection(aHR,12.47),M1 stage(aHR,6.99),and secondary OA-DLBCL(aHR,6.03;all P<0.05).The median OS was 1.68y for primary OA-DLBCL and 1.12y for secondary OA-DLBCL.CONCLUSION:A substantial proportion of patients with primary OA-DLBCL present with advanced-stage disease at diagnosis.Epiphora,atherosclerotic cardiovascular disease,HIV infection,M1 stage,and secondary OA-DLBCL are independent prognostic factors for poor survival outcomes.These findings emphasize the urgent need for optimized therapeutic strategies and early screening protocols to improve the management of OA-DLBCL,particularly in developing countries.展开更多
目的 探讨眼附属器黏膜相关淋巴组织结外边缘区(extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue, MALT)淋巴瘤伴显著浆细胞分化(plasmacytic differentiation, PCD)的临床病理特征。方法 收集3例眼附属器...目的 探讨眼附属器黏膜相关淋巴组织结外边缘区(extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue, MALT)淋巴瘤伴显著浆细胞分化(plasmacytic differentiation, PCD)的临床病理特征。方法 收集3例眼附属器MALT淋巴瘤伴显著PCD临床病理资料,采用MaxVision两步法进行免疫组化检测、BIOMED-2方法进行基因重排检测,并复习文献。结果 3例眼附属器MALT淋巴瘤伴显著PCD患者为1例男性,2例女性,中位年龄56岁,组织学表现为肿瘤性小B细胞成分少,主要局限在边缘区,单克隆性PCD细胞数量众多,在扩张的滤泡间区弥漫浸润、融合成片。免疫组化染色显示PCD细胞MUM1、CD38和(或)CD138阳性,Kappa或Lambda轻链限制性表达。基因重排结果显示IGH、IGK基因克隆性重排阳性。结论 眼附属器MALT淋巴瘤伴显著PCD罕见,与多种浆细胞众多的良恶性病变鉴别时有一定困难,诊断时需要综合判断。展开更多
间变大细胞淋巴瘤(anaplastic large cell lymphoma,ALCL)是一种侵袭性强且具有高度异质性的T细胞淋巴瘤^([1])。根据WHO造血与淋巴组织肿瘤分类,ALCL被细分为4种亚型,其中包括原发系统性间变大细胞淋巴瘤(systemic anaplastic large ce...间变大细胞淋巴瘤(anaplastic large cell lymphoma,ALCL)是一种侵袭性强且具有高度异质性的T细胞淋巴瘤^([1])。根据WHO造血与淋巴组织肿瘤分类,ALCL被细分为4种亚型,其中包括原发系统性间变大细胞淋巴瘤(systemic anaplastic large cell lymphoma,sALCL)淋巴瘤激酶(anaplastic lymphoma kinase,ALK)(+),sALCL ALK(-),原发性皮肤型ALCL和乳房假体相关ALCL^([2])。原发性皮肤ALCL是一种CD30(+)的原发性皮肤淋巴增生性疾病,其生存率高,是真菌病之后第二常见的皮肤淋巴瘤^([3-4]).展开更多
基金Supported by the Faculty of Medicine,Prince of Songkla University.Wainipitapong S has received grants from the Faculty of Medicine,Prince of Songkla University。
文摘AIM:To investigate the clinical characteristics and treatment outcomes,including visual function and overall survival(OS)of patients with ocular adnexal diffuse large B-cell lymphoma(OA-DLBCL).METHODS:This retrospective cohort study enrolled 29 patients diagnosed with OA-DLBCL based on histopathological biopsy between 2006 and 2023.Patients were stratified into two subgroups:primary OA-DLBCL(no prior history of lymphoma)and secondary OA-DLBCL(history of DLBCL at non-ocular adnexal sites).OS was defined as the time interval from OA-DLBCL diagnosis to death from any cause.Survival analysis was performed using the Kaplan–Meier method,and prognostic factors affecting OS were identified using multivariate Cox proportional hazards regression with a stepwise selection approach.RESULTS:The cohort included 24 patients with primary OA-DLBCL(13 males,11 females;mean age:61.36±18.29y)and 5 patients with secondary OA-DLBCL(2 males,3 females;mean age:50.94±18.17y).Among the primary OA-DLBCL subgroup,12 patients(50%)presented with advanced disease(Ann Arbor stage IIIE–IV),and 16 patients(66%)were classified as T4 disease according to the tumor-node-metastasis(TNM)staging system.The mean final visual acuity was 1.72±1.10 in the primary group and 0.90±1.18 in the secondary group.The 5-year OS rate for the entire cohort was 27.7%.Multivariate analysis identified five factors significantly associated with poor survival outcomes:epiphora[adjusted hazard ratio(aHR),36.95],atherosclerotic cardiovascular disease(aHR,10.08),human immunodeficiency virus(HIV)infection(aHR,12.47),M1 stage(aHR,6.99),and secondary OA-DLBCL(aHR,6.03;all P<0.05).The median OS was 1.68y for primary OA-DLBCL and 1.12y for secondary OA-DLBCL.CONCLUSION:A substantial proportion of patients with primary OA-DLBCL present with advanced-stage disease at diagnosis.Epiphora,atherosclerotic cardiovascular disease,HIV infection,M1 stage,and secondary OA-DLBCL are independent prognostic factors for poor survival outcomes.These findings emphasize the urgent need for optimized therapeutic strategies and early screening protocols to improve the management of OA-DLBCL,particularly in developing countries.
